Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (7772)	6/1/1999 2:38:00 PM
From: DaiS	Read Replies (1) \| Respond to of 9523

Brander, <<Pfizer has never pushed the use of their product (Zoloft) for the treatment in PE.>> The premature ejeculatin patent relates to zoloft: 164.195.100.11 And it was granted in 1990! OK Pfizer will generate earnings from the use of zoloft for treating PE since there cannot possibly be a PCP anywhere (let alone a specialist like you) unaware of it's application in treating PE. But my puzzle is why do Pfizer not promote this use since is should massively increase earnings. We know that many men will not come forward for treatment unless they become aware of a cure ?? My conjecture is that it would probably be bad publicity for Pfizer to push what is regarded as an antidepressant for this use. Well, Pentech do not agree with me for they have Prozac and Paxil in phase II for premature ejaculation. pentech-inc.com DaiS